Post-genomic approaches to exploring neuropeptide gene mis-expression in disease

Neuropeptides

Volumn 38, Issue 1, 2004, Pages 1-15

  MacKenzie, Alasdair ^a   Quinn, John P ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cis regulatory regions; Evolutionary conservation; Gene regulation; Neuropeptides; Pipmaker; Polymorphisms and disease; Preprotachykinin a; Transcription factors; Transgenic mice; Vista

Indexed keywords

BETA GALACTOSIDASE; DNA; DNA FRAGMENT; NEUROPEPTIDE; SEROTONIN TRANSPORTER; TRANSCRIPTION FACTOR;

BACTERIAL ARTIFICIAL CHROMOSOME; BIOINFORMATICS; CIS REGULATORY REGION; COMPUTER ANALYSIS; DNA POLYMORPHISM; DNA SEQUENCE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; GENE VECTOR; GENETIC ANALYSIS; GENETIC CODE; GENETIC CONSERVATION; GENOME; HUMAN; IN VIVO STUDY; LINKAGE ANALYSIS; NEUROLOGIC DISEASE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PUFFER FISH; REGULATORY SEQUENCE; REVIEW; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; TRANSGENIC ANIMAL;

MUS MUSCULUS; TAKIFUGU; TETRAODONTIDAE; VERTEBRATA;

EID: 1642412760     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2003.09.004     Document Type: Review

References (73)

1. Agalioti, T., Lomvardas, S., Parekh, B., Yie, J., Maniatis, T., Thanos, D., 2000. Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell 103, 667-678.
2. Amouyel, P., 2002. Genetic susceptibility to ageing-associated diseases. C. R. Biol. 325, 741-745.
3. Carroll, S.B., 2003. Genetics and the making of Homo sapiens. Nature 422, 849-857.
4. Carter, D., Chakalova, L., Osborne, C.S., Dai, Y.F., Fraser, P., 2002. Long-range chromatin regulatory interactions in vivo. Nat. Genet. 32, 623-626.
5. Castelli-Gair, J., 1998. Implications of the spatial and temporal regulation of Hox genes on development and evolution. Int. J. Dev. Biol. 42, 437-444.
6. Cheah, S.S., Behringer, R.R., 2000. Gene-targeting strategies. Methods Mol. Biol. 136, 455-463.
7. Cheung, V.G., Spielman, R.S., 2002. The genetics of variation in gene expression. Nat. Genet. Suppl. 32, 522-525.
8. Eichner, J.E., Dunn, S.T., Perveen, G., Thompson, D.M., Stewart, K.E., Stroehla, B.C., 2002. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155, 487-495.
9. Faustino, N.A., Cooper, T.A., 2003. Pre-mRNA splicing and human disease. Genes Dev. 17, 419-437.
10. Fiskerstrand, C., Quinn, J.P., 1996. The molecular biology of preprotachykinin-A gene expression. Neuropeptides 30, 602-610.
11. Fiskerstrand, C.E., Lovejoy, E.A., Quinn, J.P., 1999a. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 458, 171-174.
12. Fiskerstrand, C.E., Newey, P., Ebrahimi, B., Gerrard, L., Harrison, P., McGregor, G.P., Quinn, J.P., 1999b. Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3′ of the major transcriptional start site. Biochem. J. 341, 847-852.
13. Gao, B., Kunos, G., 2000. DNase I footprinting analysis of transcription factors recognizing adrenergic receptor gene promoter sequences. Methods Mol. Biol. 126, 419-429.
14. Gard, P.R., 2002. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. 438, 1-14.
15. Griffin, C., Kleinjan, D.A., Doe, B., vanHeyningen, V., 2002. New 3′ elements control Pax6 expression in the developing pretectum, neural retina and olfactory region. Mech. Dev. 112, 89-100.
16. Harlan, R.E., Garcia, M.M., et al., 1989. Cellular localization of substance P- and neurokinin A-encoding preprotachykinin mRNA in the female rat brain. J. Comp. Neurol. 287 (2), 179-212.
17. Hokfelt, T., Pernow, B., Wahren, J., 2001. Substance P: a pioneer amongst neuropeptides. J. Intern. Med. 249, 27-40.
18. Hokfelt, T., Broberger, C., Xu, Z.Q., Sergeyev, V., Ubink, R., Diez, M., 2000. Neuropeptides - an overview. Neuropharmacology 39, 1337-1356.
19. Howell, W.M., Calder, P.C., Grimble, R.F., 2002. Gene polymorphisms, inflammatory diseases and cancer. Proc. Nutr. Soc. 61, 447-456.
20. Jordan, I.K., Rogozin, I.B., Glazko, G.V., Koonin, E.V., 2003. Origin of a substantial fraction of human regulatory sequences from transposable elements. Trends Genet. 19, 68-72.
21. Jurka, J., 2000. Repbase update: a database and an electronic journal of repetitive elements. Trends Genet. 16, 418-420.
22. Kim, S.J., Young, L.J., Gonen, D., Veenstra-VanderWeele, J., Courchesne, R., Courchesne, E., Lord, C., Leventhal, B.L., Cook Jr., E.H., Insel, T.R., 2002. Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol. Psychiatry. 7, 503-507.
23. Kiyohara, C., Otsu, A., Shirakawa, T., Fukuda, S., Hopkin, J.M., 2002. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 37, 241-256.
24. Kontula, K., Ehnholm, C., 1996. Regulatory mutations in human lipoprotein disorders and atherosclerosis. Curr. Opin. Lipidol. 7, 64-68.
25. Kuhn, R., Schwenk, F., Aguet, M., Rajewsky, K., 1995. Inducible gene targeting in mice. Science 269, 1427-1429.
26. Landgraf, R., 2003. Neurobiology and genetics of anxiety in an animal model. Nervenarzt 74, 274-278.
27. Laws, S.M., Hone, E., Gandy, S., Martins, R.N., 2003. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J. Neurochem. 84, 1215-1236.
28. Lettice, L.A., Heaney, S.J., Purdie, L.A., Li, L., de Beer, P., Oostra, B.A., Goode, D., Elgar, G., Hill, R.E., de Graaff, E., 2003. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum. Mol. Genet. 12, 1725-1735.
29. Lettice, L.A., Horikoshi, T., Heaney, S.J., van Baren, M.J., van der Linde, H.C., Breedveld, G.J., Joosse, M., Akarsu, N., Oostra, B.A., Endo, N., Shibata, M., Suzuki, M., Takahashi, E., Shinka, T., Nakahori, Y., Ayusawa, D., Nakabayashi, K., Scherer, S.W., Heutink, P., Hill, R.E., Noji, S., 2002. Disruption of a long-range cis-acting regulator for Shh causes preaxial polydactyly. Proc. Natl. Acad. Sci. USA 99, 7548-7553.
30. Liu, G., Zhao, S., Bailey, J.A., Sahinalp, S.C., Alkan, C., Tuzun, E., Green, E.D., Eichler, E.E., 2003. Analysis of primate genomic variation reveals a repeat-driven expansion of the human genome. Genome Res. 13, 358-368.
31. Loots, G.G., Ovcharenko, I., Pachter, L., Dubchak, I., Rubin, E.M., 2002. rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res. 12, 832-839 (doi).
32. Loots, G.G., Locksley, R.M., Blankespoor, C.M., Wang, Z.E., Miller, W., Rubin, E.M., Frazer, K.A., 2000. Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288, 136-140.
33. Love, J.D., Gooch, J.T., Nagy, L., Chatterjee, V.K., Schwabe, J.W., 2000. Transcriptional repression by nuclear receptors: mechanisms and role in disease. Biochem. Soc. Trans. 28, 390-396.
34. MacKenzie, A., Quinn, J., 1999. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc. Natl. Acad. Sci. USA 96, 15251-15255.
35. MacKenzie, A., Quinn, J., 2002. A yeast artificial chromosome containing the human preprotachykinin-A gene expresses substance P in mice and drives appropriate marker gene expression during early brain embryogenesis. Mol. Cell. Neurosci. 19, 72-87.
36. MacKenzie, A., Purdie, L., Davidson, D., Collinson, M., Hill, R.E., 1997. Two enhancer domains control early aspects of the complex expression pattern of Msxl. Mech. Dev. 62, 29-40.
37. MacKenzie, A., Payne, C., Boyle, S., Clarke, A.R., Quinn, J.P., 2000. The human preprotachykinin-A gene promoter has been highly conserved and can drive human-like marker gene expression in the adult mouse CNS. Mol. Cell. Neurosci. 16, 620-630.
38. Magdaleno, S.M., Curran, T., 1999. Gene dosage in mice - BAC to the future. Nat. Genet. 22, 319-320 (news; comment).
39. Matys, V., Fricke, E., Geffers, R., Gossling, E., Haubrock, M., Hehl, R., Kornischer, K., Karas, D., Kel, A.E., Kel-Margoulis, O.V., Kloos, D.U., Land, S., Lewicki-Potapov, B., Michael, H., Munch, R., Reuter, I., Rotert, S., Saxel, H., Scheer, M., Thiele, S., Wingender, E., 2003. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 31, 374-378.
40. Mayer, P., Hollt, V., 2001. Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol. Ther. 91, 167-177.
41. Mayor, C., Brudno, M., Schwartz, J.R., Poliakov, A., Rubin, E.M., Frazer, K.A., Pachter, L.S., Dubchak, I., 2000. VISTA : visualizing global DNA sequence alignments of arbitrary length. Bioinformatics 16, 1046-1047.
42. McDevitt, M.A., Fujiwara, Y., Shivdasani, R.A., Orkin, S.H., 1997. An upstream, DNase I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice. Proc. Natl. Acad. Sci. USA 94, 7976-7981.
43. Mendell, J.T., Dietz, H.C., 2001. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 107, 411-114.
44. Michelhaugh, S.K., Fiskerstrand, C., Lovejoy, E., Bannon, M.J., Quinn, J.P., 2001. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances***** transcription in dopamine neurons. J. Neurochem. 79, 1033-1038.
45. Miles, C., Elgar, G., Coles, E., Kleinjan, D.J., vanHeyningen, V., Hastie, N., 1998. Complete sequencing of the Fugu WAGR region from WT1 to PAX6: dramatic compaction and conservation of synteny with human chromosome 11p13. Proc. Natl. Acad. Sci. USA 95, 13068-13072.
46. Miles, C.G., Rankin, L., Smith, S.I., Niksic, M., Elgar, G., Hastie, N.D., 2003. Faithful expression of a tagged Fugu WT1 protein from a genomic transgene in zebrafish: efficient splicing of pufferfish genes in zebrafish but not mice. Nucleic Acids Res. 31, 2795-2802.
47. Millward-Sadler, S.J., Mackenzie, A., Wright, M.O., Lee, H.S., Elliot, K., Gerrard, L., Fiskerstrand, C.E., Salter, D.M., Quinn, J.P., 2003. Tachykinin expression in cartilage and function in human articular chondrocyte mechanotransduction. Arthritis Rheum. 48, 146-156.
48. Monaco, A.P., Larin, Z., 1994. YACs, BACs, PACs and MACs: artificial chromosomes as research tools. Trends Biotechnol. 12, 280-286.
49. Quinn, J.P., Fiskerstrand, C.E., Gerrard, L., MacKenzie, A., Payne, C.M., 2000. Molecular models to analyse preprotachykinin-A expression and function. Neuropeptides 34, 292-302.
50. Rajewsky, K., Gu, H., Kuhn, R., Betz, U.A., Muller, W., Roes, J., Schwenk, F., 1996. Conditional gene targeting. J. Clin. Invest. 98, 600-603.
51. Randazzo, F.M., Cribbs, D.L., Kaufman, T.C., 1991. Rescue and regulation of proboscipedia: a homeotic gene of the Antennapedia Complex. Development 113, 257-271.
52. Reif, A., Lesch, K.P., 2003. Toward a molecular architecture of personality. Behav. Brain. Res. 139, 1-20.
53. Reiterova, J., Tesar, V., Merta, M., 2001. Effect of angiotensin- converting enzyme insertion-deletion polymorphism on progression of renal and cardiovascular diseases. Cas Lek Cesk 140, 267-271.
54. Santini, S., Boore, J.L., Meyer, A., 2003. Evolutionary conservation of regulatory elements in vertebrate hox gene clusters. Genome Res. 13, 1111-1122.
55. Schroeter, S., Blakely, R.D., 1996. Drug targets in the embryo. Studies on the cocaine- and antidepressant-sensitive serotonin transporter. Ann. N.Y. Acad. Sci. 801, 239-255.
56. Schwartz, S., Zhang, Z., Frazer, K.A., Smit, A., Riemer, C., Bouck, J., Gibbs, R., Hardison, R., Miller, W., 2000. PipMaker - a web server for aligning two genomic DNA sequences. Genome Res. 10, 577-586.
57. Shashikant, C.S., Kim, C.B., Borbely, M.A., Wang, W.C., Ruddle, F.H., 1998. Comparative studies on mammalian Hoxc8 early enhancer sequence reveal a baleen whale-specific deletion of a cis-acting element. Proc. Natl. Acad. Sci. USA 95, 15446-15451.
58. Shi, X., Eckhardt, L.A., 2001. Deletional analyses reveal an essential role for the hs3b/hs4 IgH 3′ enhancer pair in an Ig-secreting but not an earlier-stage B cell line. Int. Immunol. 13, 1003-1012.
59. Sieweke, M., 2000. Detection of transcription factor partners with a yeast one hybrid screen. Methods Mol. Biol. 130, 59-77.
60. Silver, S.C., Hunt 3rd, S.W., 1993. Techniques for cloning cDNAs encoding interactive transcriptional regulatory proteins. Mol. Biol. Rep. 17, 155-165.
61. Takahashi, T., Guron, C., Shetty, S., Matsui, H., Raghow, R., 1997. A minimal murine Msx-1 gene promoter. Organization of its cis-regulatory motifs and their role in transcriptional activation in cells in culture and in transgenic mice. J. Biol. Chem. 272, 22667-22678.
62. van Heel, DA., Udalova, I.A., De Silva, A.P., McGovern, D.P., Kinouchi, Y., Hull, J., Lench, N.J., Cardon, L.R., Carey, A.H., Jewell, D.P., Kwiatkowski, D., 2002. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum. Mol. Genet. 11, 1281-1289.
63. Vercelli, D., 2002. Genetics of IL-13 and functional relevance of IL-13 variants. Curr. Opin. Allergy Clin. Immunol. 2, 389-393.
64. von Euler, U.S., Gaddum, J.H., 1931. An unidentified depressor substance in certain tissue extracts. Journal of Physiology 72, 74-87.
65. Wahle, M., Krause, A., Pierer, M., Hantzschel, H., Baerwald, C.G., 2002. Immunopathogenesis of rheumatic diseases in the context of neuroendocrine interactions. Ann. N.Y. Acad. Sci. 966, 355-364.
66. Wang, H.L., Wu, T., Chang, W.T., Li, A.H., Chen, M.S., Wu, C.Y., Fang, W., 2000. Point mutation associated with X-linked dominant Charcot-Marie-Tooth disease impairs the P2 promoter activity of human connexin-32 gene. Brain Res. Mol. Brain Res. 78, 146-153.
67. Wang, Z., Young, L.J., 1997. Ontogeny of oxytocin and vasopressin receptor binding in the lateral septum in prairie and montane voles. Brain Res. Dev. Brain Res. 104, 191-195.
68. Wang, Z., Young, L.J., Liu, Y., Insel, T.R., 1997. Species differences in vasopressin receptor binding are evident early in development: comparative anatomic studies in prairie and montane voles. J. Comp. Neurol. 378, 535-546.
69. Warden, M.K., Young 3rd, W.S., 1998. Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system. J. Comp. Neurol. 272 (1), 90-113.
70. Wasserman, W.W., Fickett, J.W., 1998. Identification of regulatory regions which confer muscle-specific gene expression. J. Mol. Biol. 278, 167-181.
71. Wasserman, W.W., Palumbo, M., Thompson, W., Fickett, J.W., Lawrence, C.E., 2000. Human-mouse genome comparisons to locate regulatory sites. Nat. Genet. 26, 225-228.
72. Yanagisawa, H., Clouthier, D.E., Richardson, J.A., Charite, J., Olson, E.N., 2003. Targeted deletion of a branchial arch-specific enhancer reveals a role of dHAND in craniofacial development. Development 130, 1069-1078.
73. Zelazowski, P., Shen, Y., Snapper, C.M., 2000. NF-kappaB/p50 and NF-kappaB/c-Rel differentially regulate the activity of the 3′alphaE-hsl, 2 enhancer in normal murine B cells in an activation-dependent manner. Int. Immunol. 12, 1167-1172.